Shakil Khan, MD
Cardiology · Midlothian, VANPI 1043343122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $989 and has fallen 88.3% since, to $116 in 2025.
Across 209 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$586
- Novartis$553
- Amgen$513
- Pfizer$320
- AstraZeneca$249
- Novo Nordisk$163
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,71495%
- Education$682%
- Entertainment$1253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $586 |
| Novartis | 30 | $553 |
| Amgen | 29 | $513 |
| Pfizer | 20 | $320 |
| AstraZeneca | 14 | $249 |
| Novo Nordisk | 3 | $163 |
| Johnson & Johnson | 9 | $144 |
| Boston Scientific | 5 | $133 |
| Kestra Medical Technology Services, Inc. | 4 | $125 |
| Esperion Therapeutics, Inc. | 6 | $109 |
| Biosense Webster, Inc. | 1 | $101 |
| Lundbeck LLC | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Astellas Pharma US Inc | 4 | $81 |
| Abbott | 4 | $73 |
| Edwards Lifesciences | 4 | $65 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Abiomed | 2 | $37 |
| Cvrx, Inc. | 1 | $35 |
| Atricure, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 2 | $30 |
| Gilead | 2 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $20 |
| AbbVie | 1 | $19 |
| Medicomp Inc | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$101
How this compares
Too few cardiology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 892 | $1,026,034 |
| EntrestoSacubitril/Valsartan | 289 | $361,281 |
| JardianceEmpagliflozin | 185 | $205,570 |
| Repatha SureclickEvolocumab | 157 | $160,236 |
| XareltoRivaroxaban | 94 | $96,485 |
| Praluent PenAlirocumab | 48 | $36,059 |
| Ezetimibe | 562 | $14,087 |
| Rosuvastatin Calcium | 927 | $12,886 |
| Metoprolol Succinate | 762 | $9,088 |
| Bumetanide | 199 | $6,629 |
| Eplerenone | 64 | $6,608 |
| Atorvastatin Calcium | 679 | $6,330 |
| Nebivolol Hcl | 94 | $6,117 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $5,966 |
| Losartan Potassium | 566 | $5,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $320 | $1,026,034892 claims |
| NovartisEntresto | $553 | $361,281289 claims |
| Boehringer IngelheimJardiance | $586 | $205,570185 claims |
| Johnson & JohnsonXarelto | $144 | $96,48594 claims |
| Esperion Therapeutics, Inc.Nexlizet | $109 | $5,96615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other cardiology in Midlothian
- Fareeha KhanVienna$66K
- John OwensRichmond$4K
- Mark WarnerRichmond$3K
- Gareth TitusSouth Boston$3K
- Derrick RidleyHampton$2K
- Massimo GiustiRichmond$2K
- Khosro ShareghiWoodbridge$985
- Rafael AriasFalls Church$514
- M ZaheerArlington$285
- Dean CarpousisArlington$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.